GLP1 Guide (Page 3)

STRIDE study: GLP1s vs peripheral artery disease (PAD)

STRIDE study: GLP1s vs peripheral artery disease (PAD)

Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)

Novo Nordisk licenses GLP1 drug from United BioTechnology, a Chinese research firm

Novo Nordisk licenses the right to sell a new GLP1 being developed in China -- 15% weight loss in 12 weeks (in an admittedly small study).

company:novo-nordisk

Novo Nordisk offers cheaper Wegovy

Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.

VK2735's manufacturing alliance with CordenPharma

VK2735's manufacturing alliance with CordenPharma

Viking secures a manufacturing alliance with CordenPharma, promising "metric tons" of production of VK2735

BRP - a new GLP1-like peptide

BRP - a new GLP1-like peptide

We dive into BRP, a possible new future for GLP1-like formulation that could be even more beneficial without the downsides.

HIMS ends compounded Semaglutide offering

Hims announces it will stop providing compounded Semaglutide, after removal from the FDA shortage list.

Semaglutide removed from shortage list

chemical:semaglutide

Semaglutide removed from shortage list

It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.

Mexico and GLP1s

Mexico and GLP1s

We explore GLP1 medical tourism, supply issues, and adoption of generic GLP1 Receptor Agonists in Mexico.

Shortages threaten corporate profits, likely to end soon

category:watercooler

Shortages threaten corporate profits, likely to end soon

We think the GLP1 shortage is going to end in the first half of 2025. Here's why.

Ozempic approved for Chronic Kidney Disease

Ozempic approved for Chronic Kidney Disease

The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.

Tradjenta: An alternative to GLP1 for Type 2 Diabetes

Tradjenta: An alternative to GLP1 for Type 2 Diabetes

We take a look at one of the alternatives to GLP1s that has been on the market a long time -- Tradjenta.

GLP1 use by younger people

category:watercooler

GLP1 use by younger people

We dig into the reports of younger people using GLP1s like Ozempic, Wegovy and others.

company:novo-nordisk

Novo's Amycretin delivers great Phase 2 results

Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.

The battle for compounded GLP1 continues

The battle for compounded GLP1 continues

The battle for compounded GLP1s rages on -- powerful organizations with profit incentives continue to push for compounded GLP1s, with consumers caught in the middle.

Government Price negotiations on Ozempic and Wegovy

Government Price negotiations on Ozempic and Wegovy

The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?

Pancreatitis and Gallstones after massive weight loss

category:side-effects

Pancreatitis and Gallstones after massive weight loss

We look into pancreatitis and gallstones issues that caused one death and more hospitalizations, caused at least in part by GLP1s

What's the best injection site for GLP1s?

What's the best injection site for GLP1s?

What's the best site for injecting Ozempic, Wegovy, Mounjaro, or Zepbound? We check anecdata, manufacturers, and 3rd parties.

Zepbound coverage for Sleep Apnea gets Agency approval

category:benefits

Zepbound coverage for Sleep Apnea gets Agency approval

Center for Medicare and Medicaid declared that Zepbound is covered by insurance for treating Sleep Apnea, given it's effectiveness.

Robert F. Kennedy Jr vs GLP1

RFK Jr.'s appointment and it's effect on GLP1s. Is it truly anti-GLP1? Or a case of tactics?

Research suggesting GLP1 is a brain drug

Research suggesting GLP1 is a brain drug

Why has modern scientific opinion shifted to GLP1 being a brain drug rather than a gut drug? We dive into the critical research paper supporting the shift.

Tirzepatide's benefits extend to Kidney Disease

usecase:kidney-disease

Tirzepatide's benefits extend to Kidney Disease

Tirzepatide (Mounjaro, Zepbound) shows results in weight loss and Hba1c reduction for southerners, critical to kidney disease treatment.

Another Generic Liraglutide launch: Hikma Phamaceuticals

A new player enters the generic GLP1 market - Hikma Pharmaceuticals. As the second generic Liraglutide provider, accessibility of GLP1s has never been better.

HIMS to offer Liraglutide after shortage rule changes

HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?

Adlyxin's 2025 Patent expiry

chemical:lixisenatide

Adlyxin's 2025 Patent expiry

Aldyxin' approaching 2025 patent expiry and what it could mean for new GLP1 drugs.

Research models applied to GLP1s and Plateaus

categeory:watercooler

Research models applied to GLP1s and Plateaus

New research that shows a benefit to appetite feedback control circuits via mathematical modeling, showing the benefits of using GLP1s.